Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.51 |
| ▸ | NPC1 | O15118 | 6/20 | 0.51 |
| ▸ | RAB9A | P51151 | 6/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 2/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | VCP | P55072 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.47 |
| ▸ | RELA | Q04206 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11239265 | 0.91 | MAPT (0.57) | MAPTNPC1RAB9AGAANPSR1 | |
| SCHEMBL11248461 | 0.87 | MAPT (0.55) | MAPTNPC1RAB9AGAANPSR1 | |
| SCHEMBL11248010 | 0.87 | SIRT5 (0.52) | MAPTNPC1RAB9AGAANPSR1 | |
| SCHEMBL3612694 | 0.86 | MAPT (0.67) | MAPTNPC1RAB9AGAANPSR1 | |
| SCHEMBL11246181 | 0.86 | MAPT (0.53) | MAPTNPC1RAB9AGAANPSR1 | |
| SCHEMBL11246073 | 0.85 | MAPT (0.48) | MAPTNPC1RAB9AGAANPSR1 | |
| SCHEMBL10675056 | 0.85 | MAPT (0.50) | MAPTNPC1RAB9AGAANPSR1 | |
| SCHEMBL3606550 | 0.85 | MAPT (0.52) | MAPTNPC1RAB9AGAANPSR1 | |
| SCHEMBL3604035 | 0.84 | ATP4A (0.56) | MAPTNPC1RAB9AGAANPSR1 | |
| Bromide SCHEMBL11253435 | 0.84 | MAPT (0.51) | MAPTNPC1RAB9AGAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | claimed |
| CN-101466692-A | Thiazol-guanidine derivatives useful as a (beta) - related pathologies | ASTRAZENECA AB (SE) | 2009-06-24 | — | — | CN | claimed |
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| CN-101466692-A | Thiazol-guanidine derivatives useful as a (beta) - related pathologies | ASTRAZENECA AB (SE) | 2009-06-24 | — | — | CN | disclosed |
| EP-2010508-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007120096-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |
| US-4772622-A | 3,5-diamino-1,2,4-oxidiazoles as gastric secretion inhibitors | MERCK & CO., INC. (US) | 1988-09-20 | — | — | US | disclosed |
| EP-0089730-B1 | GUANIDINO HETEROCYCLICPHENYLAMIDINES, PROCESSES FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | ISTITUTO DE ANGELI S.p.A. (IT) | 1987-05-27 | — | — | EP | disclosed |
| US-4645841-A | ANTIULCER AGENTS | ISTITUTO DE ANGELI, S.P.A. (IT) | 1987-02-24 | — | — | US | disclosed |
| US-4548944-A | ANTIULCER, ANTISECRETORY AGENTS | ISTITUTO DE ANGELI S.P.A. (IT) | 1985-10-22 | — | — | US | disclosed |
| EP-0089730-A2 | Guanidino heterocyclicphenylamidines, processes for their preparation and their pharmaceutical use | ISTITUTO DE ANGELI S.p.A. (IT) | 1983-09-28 | — | — | EP | disclosed |
| EP-0059903-A1 | Diaminooxadiazoles, their use as gastric secretion inhibitors, and process for their preparation | MERCK & CO. INC. (US) | 1982-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | GRN, MAPT, GUCY1B1 | MAPT 2/4885NPC1 267/4885RAB9A 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.